Appendix 3H - Notification of cessation of securities Appendix 3H - Notification of cessation of securities 1 / 5 Announcement Summary Entity name ARGENT BIOPHARMA LIMITED Announcement Type New announcement Date of this announcement Tuesday September 01, 2026 Details of +securities that...
Notification of cessation of securities - RGT
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Argent Biopharma Ltd has filed a notification regarding the cessation of certain securities, specifically convertible notes, due to an agreement with the holder. Following this cessation, the company's issued capital will include a total number of ordinary fully paid securities listed on the exchange. The announcement serves to inform stakeholders about changes in the company's securities structure.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Argent Biopharma
- Appendix 4E and 2026 Annual Report
- Appendix 4G and Corporate Governance Statement
- FDA-CVM Establish INAD File for CannEpil Veterinary Program
- Proposed issue of securities - RGT
- $250,000 in Funding Received under Financing Facility
Later from Argent Biopharma
- Argent Signs NLC Licence to Expand Antiviral Portfolio
- Execution of Loan Facility Agreement
- Application for quotation of securities - RGT
- Strategic Focus on Immune Modulation and Longevity
- Date of AGM and Closing Date for Director Nominations
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma